SkyCell AG (“SkyCell”) has developed patented temperature-control technology to safely transport vaccines and biotechnology drugs by air.
SkyCell technology avoids the need for active refrigeration, lowers the costs of transport and reduces potential damage to vital pharmaceutical products. SkyCell enables pharmaceutical companies to deliver medications both safely and reliably to patients around the globe.
The demand for controlled freight environments is growing, driven by an unmet medical need for temperature-sensitive medications and an increased focus on quality throughout the transport process. SkyCell is winning major accounts with its robust, precise and versatile technology.
SkyCell is based in Zurich, Switzerland. MVM’s Hugo Harrod and Jack Tanaka have joined the SkyCell Board of Directors.